CD14 and TNfa promoter polymorphisms in patients with acute arthritis. Special reference to development of chronic spondyloarthropathy

Scand J Rheumatol. 2002;31(6):355-61. doi: 10.1080/030097402320817086.

Abstract

Objective: To examine CD14 and TNFalpha gene polymorphisms in early arthritis in relation to clinical outcome.

Methods: We studied 141 Caucasians who had had early arthritis 10 to 38 years earlier. We analysed CD14 (-159) and TNFalpha (-238, -308, -376) polymorphisms using a novel cycle minisequencing method. DNA pools from 370 Caucasian blood donors served as controls.

Results: CD14 (-159)C-->T allele frequencies were comparable among patients and controls (39% vs 40%). Fifty men and 42 women had recovered while 24 men and six women had chronic spondyloarthropathy (SpA). Mutant T allele frequency was higher in the chronic SpA group than in the recovered group in women (75% vs 32%, relative risk 1.3, 95% confidence limit 1.1 to 1.6, P = 0.011), but not in men (38% vs 44%). All female patients with chronic SpA had CD14 (-159)T allele and none had a possibly protective TNFalpha (-308)G-->A allele.

Conclusions: Possession of CD14 (-159)T allele does not increase risk of ReA but may increase susceptibility of female patients to development of chronic SpA.

MeSH terms

  • Acute Disease
  • Adult
  • Age of Onset
  • Aged
  • Arthritis, Reactive / genetics*
  • Chronic Disease
  • DNA Primers
  • Female
  • Genetic Predisposition to Disease*
  • Humans
  • Lipopolysaccharide Receptors / genetics*
  • Male
  • Middle Aged
  • Polymerase Chain Reaction
  • Polymorphism, Genetic*
  • Prohibitins
  • Promoter Regions, Genetic / genetics*
  • Sex Factors
  • Spondylarthropathies / genetics*
  • Tumor Necrosis Factor-alpha / genetics*

Substances

  • DNA Primers
  • Lipopolysaccharide Receptors
  • PHB2 protein, human
  • Prohibitins
  • Tumor Necrosis Factor-alpha